Roland Mory

TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity

Florent G. Revel, Jean‐Luc Moreau, Raul R. Gainetdinov et al. · Proceedings of the National Academy of Sciences · 2011 · 365 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight

F. Revel, J‐L Moreau, Bruno Pouzet et al. · Molecular Psychiatry · 2012 · 286 citations

Medicine, Neuroscience, Pharmacology +16

Selective GlyT1 Inhibitors: Discovery of [4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((<i>S</i>)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a Promising Novel Medicine To Treat Schizophrenia

Emmanuel Pinard, Alexander Alanine, Daniela Alberati et al. · Journal of Medicinal Chemistry · 2010 · 134 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia

Daniela Alberati, Jean‐Luc Moreau, Judith A. Lengyel et al. · Neuropharmacology · 2011 · 126 citations

Medicine, Pharmacology, Psychiatry +10

Deficits in reward sensitivity in a neurodevelopmental rat model of schizophrenia

Laurent Gaudet, P. Mortas, Roland Mory et al. · Psychopharmacology · 2002 · 59 citations

Medicine, Neurobiology, Neuroscience +12